Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on May 12, 2025
The EDR Test That Matters - AV-Comparatives to publish the first truly stealth-based EDR test
EIN Presswire
·
May 12, 2025
AV-Comparatives to publish the first truly stealth-based EDR test at the end of May, exposing how today’s security tools fare against APT cyberattacks. INNSBRUCK, TYROL, AUSTRIA, May 12, 2025 /EINPresswire.com/ -- AV-Comparatives, the world-renowned …
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
GlobeNewswire
·
May 12, 2025
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally …
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May …
Quipt Home Medical Reports Fiscal Second Quarter 2025 Results
GlobeNewswire
·
May 12, 2025
CINCINNATI, May 12, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fiscal second quarter 2025 …
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
GlobeNewswire
·
May 12, 2025
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide …
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context …
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
GlobeNewswire
·
May 12, 2025
KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD). Obesity-associated cardiometabolic preclinical …
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapy SEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in …
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
May 12, 2025
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of TNX- …
Vireo Growth Inc. Announces Closing of WholesomeCo Cannabis & Arches Merger Transactions
GlobeNewswire
·
May 12, 2025
– Acquisitions strengthen profitability and competitive position with proprietary technology platform – – Missouri and Nevada transactions remain on track to close during the second quarter of 2025 – MINNEAPOLIS, May 12, 2025 (GLOBE NEWSWIRE) -- Vireo …
Cellectis Reports Financial Results for the First Quarter 2025
GlobeNewswire
·
May 12, 2025
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 …
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
GlobeNewswire
·
May 12, 2025
FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a …
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European …
Maravai Lifesciences Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first …
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 12, 2025
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise …
LifeMD to Participate in Three Investor Conferences During May
GlobeNewswire
·
May 12, 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May: H.C. …
Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference
GlobeNewswire
·
May 12, 2025
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2025 …
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK
GlobeNewswire
·
May 12, 2025
LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets …
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity Bolt is running a …
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152, …